AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21756523
Drug: IV hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV hydrocortisone (HC) followed by oral prednisolone (200 mg 6 hourly until discharge, followed by prednisolone 0.75 mg/kg/day for 2 weeks)
Trial: 19888784
Drug: ALO-01 whole
RxNorm normalized name: ALOE ARBORESCENS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO-01 whole (60 mg capsules)
Trial: 19888784
Drug: ALO-01 crushed
RxNorm normalized name: aloe polysaccharide 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO-01 crushed (60 mg capsules)
Trial: 19888784
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate solution (MSS) (120 mg)
Trial: 7595265
Drug: Pharmacotherapy consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy consultation
Trial: 31416827
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg)
Trial: 773507
Drug: Oxygen administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administered by MC mask throughout the first 24 hours in hospital
Trial: 773507
Drug: Air administered
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air administered by MC mask throughout the first 24 hours in hospital
Trial: 14757900
Drug: Interdisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary rehabilitation program (7 weeks duration, including pain school, cognitive behavioral therapy, gradual withdrawal of pain-relieving drugs)
Trial: 971966
Drug: Home care
RxNorm normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home care as part of treatment
Trial: 971966
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hospital treatment)
Trial: 25138765
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (500 mg on day 1 and then 250 mg/day for 5 days)
Trial: 25138765
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (200 mg/day for 1 month)
Trial: 23161899
Drug: GLPG0259 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0259 (50 mg once daily)
Trial: 22686551
Drug: Telephone-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive-behavioral therapy (CBT)
Trial: 10684841
Drug: Topical nipradilol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nipradilol (0.25%)
Trial: 9344406
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) with tacrine (80 mg/day, 120 mg/day, or 160 mg/day)
Trial: 9344406
Drug: Tacrine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (80 mg/day, 120 mg/day, or 160 mg/day) without ERT
Trial: 2943811
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (plasma-derived and recombinant)
Trial: 31971071
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VRT and CPT (COMB)
Trial: 29846887
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily (young subjects); 25 mg or 50 mg once daily (elderly subjects)
Trial: 26713415
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment for patellofemoral OA
Trial: 6742895
Drug: Intraarticular steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular steroids
Trial: 25176136
Drug: Ivabradine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (up to 10 mg twice daily)
Trial: 12475163
Drug: Mixed treatment
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed treatment (control appliance followed by stabilization appliance)
Trial: 479385
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nefopam hydrochloride
Trial: 479385
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg nefopam hydrochloride
Trial: 30929028
Drug: Intervention patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention patients with high pre‐treatment anxiety
Trial: 28127827
Drug: Pragmatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic treatment of the lumbar spine and prescriptive treatment of bilateral hips (LBP + HIP)
Trial: 28127827
Drug: Pragmatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic treatment of the lumbar spine only (LBP)
Trial: 25830267
Drug: Arthroscopic shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic shoulder capsular release and manipulation, followed by a stretching program (twice daily for at least 15 minutes for 3 months)
Trial: 25830267
Drug: Home therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home therapy program consisting of terminal range of motion low-grade stretches (twice daily for at least 15 minutes for 3 months)
Trial: 21339317
Drug: Optimal pharmacological
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacological treatment (OPT)
Trial: 10356602
Drug: Anticoagulants (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (specific type not mentioned)
Trial: 1826454
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) administered alone (273 men)
Trial: 1826454
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) with escalating doses (3, 9, and 18 million I.U. daily for 3 days, then 36 million I.U. daily)
Trial: 1826454
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) at a dose of 36 million I.U. daily for approximately 10 weeks followed by maintenance schedule
Trial: 25123061
Drug: DHA-rich intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich intervention supplement capsules consumed over the course of pregnancy
Trial: 19243711
Drug: Cyclobenzaprine extended-release
RxNorm normalized name: cyclobenzaprine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine extended-release 15 mg
Trial: 19243711
Drug: Cyclobenzaprine extended-release
RxNorm normalized name: cyclobenzaprine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine extended-release 30 mg
Trial: 15764049
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel 0.1% plus clindamycin topical solution 1%
Trial: 15764049
Drug: Clindamycin topical
RxNorm normalized name: clindamycin topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin topical solution 1% alone
Trial: 15764049
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel 0.1% alone
Trial: 9639376
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor candoxatrilat (125 nmol/min)
Trial: 9639376
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor thiorphan (30 nmol/min) after placebo
Trial: 9639376
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor thiorphan (30 nmol/min) after enalapril (20 mg)
Trial: 9639376
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor thiorphan (30 nmol/min)
Trial: 9639376
Drug: Endothelin ETA
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin ETA antagonist BQ‐123 (100 nmol/min)
Trial: 9639376
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor thiorphan (30 nmol/min) in hypertensive patients
Trial: 8404404
Drug: Olsalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (2 g daily)
Trial: 8079106
Drug: Mesalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (2 g or 6 g daily)
Trial: 8079106
Drug: Control (pre-medication)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (pre-medication)
Trial: 1269844
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injections
Trial: 30969032
Drug: Combined 8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 8.3 mg Nestorone® and 62.5 mg Testosterone gel (Nes-T)
Trial: 30969032
Drug: 62.7 mg
RxNorm normalized name: AVOBENZONE 25.1 mg in 1 mL / HOMOSALATE 62.7 mg in 1 mL / OCTISALATE 41.8 mg in 1 mL / OCTOCRYLENE 22.9 mg in 1 mL / OXYBENZONE 16.7 mg in 1 mL TOPICAL LOTION [Australian Gold BOAD SPECTRUM SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.7 mg Testosterone gel
Trial: 31323067
Drug: Macintosh laryngoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macintosh laryngoscope (ML)
Trial: 22333218
Drug: Bosentan treatment
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan treatment
Trial: 12511540
Drug: BNP infusion
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP infusion (60, 120, and 180 pmol/min)
Trial: 12511540
Drug: BNP infusion
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP infusion (180 pmol/min)
Trial: 8965117
Drug: Copolymer 1
RxNorm normalized name: glatiramer (copolymer 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copolymer 1 (Copaxone) 20 mg daily subcutaneous injection for at least 1 year
Trial: 1814318
Drug: Oral magnesium-lactate-citrate
RxNorm normalized name: calcium lactate / magnesium citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral magnesium-lactate-citrate for 6 weeks
Trial: 1814318
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (30 mmol daily for 7 days)
Trial: 30496533
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Trial: 30496533
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment for Pain (CBT-P)
Trial: 24380637
Drug: Run-off CTA
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-off CTA with 40 mL of contrast medium (injection rate of 6 mL/s)
Trial: 19527338
Drug: TA-loaded lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-loaded lipid nanocarriers (TA-LNCs) incorporated into a hydrophilic gel and foam
Trial: 19527338
Drug: Saturated TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated TA solution in silicon oil
Trial: 17475733
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (augmentation with citalopram)
Trial: 17475733
Drug: Medication augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication augmentation (sustained-release bupropion or buspirone)
Trial: 17475733
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to cognitive therapy
Trial: 17475733
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to another antidepressant (sertraline, sustained-release bupropion, or extended-release venlafaxine)
Trial: 15064269
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 75 ng*mL(‐1)
Trial: 15064269
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 0 ng*mL(‐1) (Group 0)
Trial: 15064269
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 25 ng*mL(‐1) (Group 25)
Trial: 15064269
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 50 ng*mL(‐1) (Group 50)
Trial: 15064269
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at 75 ng*mL(‐1) (Group 75)
Trial: 8507125
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of K8515 ingested in a prehydrated form three times a day with meals
Trial: 8507125
Drug: 6.7 g
RxNorm normalized name: ALCOHOL 16.7 g in 30 mL TOPICAL SPRAY [HS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.7 g of K8515 three times a day
Trial: 24231560
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (prednisolone 4 mg/kg/day over 1 week and 2mg/kg/day for the next 3 weeks)
Trial: 24231560
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (prednisolone 4 mg/kg/day over 4 weeks)
Trial: 22402793
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine patch (Lidoderm(®), Endo Pharmaceuticals)
Trial: 20097702
Drug: Dalcetrapib 900
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 900 mg/day with atorvastatin
Trial: 19069460
Drug: Bismuth tri‐potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth tri‐potassium di‐citrate (De-Nol) 120 mg thrice daily with meteospasmyl (spasmolytic and antifoaming agent) for 3 weeks
Trial: 19069460
Drug: Aluminium phosphate
RxNorm normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminium phosphate with meteospasmyl (1 capsule thrice daily) for 3 weeks
Trial: 16162940
Drug: Simvastatin, 80
RxNorm normalized name: Simvastatin, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 80 mg/day
Trial: 14702121
Drug: Telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg/day for 10 days
Trial: 14702121
Drug: Clarithromycin 1000
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1000 mg/day for 10 days
Trial: 10394976
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CPFX plus 600 mg CAM (combination group)
Trial: 10394976
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CPFX (CPFX group)
Trial: 10394976
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CPFX plus 600 mg CAM (combination group) in patients with an indwelling catheter
Trial: 10394976
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CPFX (CPFX group) in patients with an indwelling catheter
Trial: 8785404
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 to 3200 mg/day) for 12 weeks
Trial: 1804644
Drug: Ro 23‐6152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23‐6152 30 mg
Trial: 1804644
Drug: Ro 23‐6152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23‐6152 80 mg
Trial: 1804644
Drug: Ro 23‐6152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23‐6152 10 mg
Trial: 27721230
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1800 mg daily for 4 months)
Trial: 25509696
Drug: Calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluconate intravenous use
Trial: 19717476
Drug: Salmeterol/Fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone propionate combination (SFC)
Trial: 18847425
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with an ACE inhibitor (perindopril) and a diuretic (indapamide) in fixed doses
Trial: 18847425
Drug: Direct renin
RxNorm normalized name: DIRECT RENIN INHIBITOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct renin inhibitors
Trial: 17145988
Drug: Overnight hospitalization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight hospitalization and abciximab bolus and infusion (group 2)
Trial: 11461738
Drug: Digoxin and
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin and diuretics
Trial: 2170885
Drug: Estrogen/progestin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen/progestin therapy
Trial: 11174874
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hormone replacement therapy)
Trial: 9179430
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (200 micrograms once daily for 14 days)
Trial: 9179430
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (for 14 days)
Trial: 23730580
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray
Trial: 8255415
Drug: 5HT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5HT group (5HT-1a agonist under normal temperature)
Trial: 3895827
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of cold carbonated water
Trial: 3895827
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of lukewarm tap water
Trial: 3895827
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of lukewarm tap water
Trial: 25382508
Drug: Autoinoculation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoinoculation therapy
Trial: 22584566
Drug: sHT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sHT treatment
Trial: 20443153
Drug: 80% inspired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% inspired oxygen via PULMANEX Hi‐Ox Mask (10 L/min)
Trial: 20443153
Drug: 30% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oxygen via nasal cannula (2 L/min)
Trial: 18536191
Drug: Fluoxetine (20‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20‐60 mg/day)
Trial: 18536191
Drug: Imipramine (50‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50‐150 mg/day)
Trial: 12462772
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g intravenous single dose)
Trial: 12462772
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propacetamol and promedol (opioid analgesic)
Trial: 7568839
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of digital subtraction and fluoroscopic spot images
Trial: 2188773
Drug: pyrazinoylguanidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrazinoylguanidine (300 mg b.i.d.)
Trial: 2188773
Drug: pyrazinoylguanidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrazinoylguanidine (600 mg b.i.d.)
Trial: 2188773
Drug: pyrazinoylguanidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrazinoylguanidine (300 mg b.i.d. for 3 days)
Trial: 2188773
Drug: pyrazinoylguanidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrazinoylguanidine (600 mg b.i.d. for 3 days)
Trial: 6777806
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg diazepam (DZ)
Trial: 6777806
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg N-desmethyldiazepam (NDDZ)